Back

FREE Webinar Recording: Digital Therapeutics & ADHD: A New Class of Medicine with Dr. Scott Kollins

$0.00

ADDA Members get access to Webinars FREE! To access, login to the member’s area, or purchase a membership.

Description

Commercially available digital therapeutics (DTx) to treat mental health conditions have been available for over a decade, and the industry has matured substantially. Currently there are thousands of apps for mental health conditions, but only a tiny fraction have chosen to seek regulatory approval and the majority of these are for mental health conditions. Here, we will describe what differentiates digital therapeutics as a class of medicine from these health and wellness apps and provide an overview of the FDA regulatory process and why it’s important. Additionally, we will highlight how digital therapeutics can fill gaps in current treatment paradigms and improve access to care. Finally, audience members will be introduced to the currently available digital therapeutics for ADHD and the data that supports their use.

Learning Objectives:

Describe what a digital therapeutic is and the FDA regulatory process
Understand the role digital therapeutics play in the treatment landscape for ADHD
Identify current digital therapeutics available for patients with ADHD and understand the data that supports their use

Who: Dr. Scott Kollins

Recorded on Oct 18, 2023

Visit Scott’s website here: https://www.akiliinteractive.com/

Commercially available digital therapeutics (DTx) to treat mental health conditions have been available for over a decade, and the industry has matured substantially. Currently there are thousands of apps for mental health conditions, but only a tiny fraction have chosen to seek regulatory approval and the majority of these are for mental health conditions. Here, we will describe what differentiates digital therapeutics as a class of medicine from these health and wellness apps and provide an overview of the FDA regulatory process and why it’s important. Additionally, we will highlight how digital therapeutics can fill gaps in current treatment paradigms and improve access to care. Finally, audience members will be introduced to the currently available digital therapeutics for ADHD and the data that supports their use.

Learning Objectives:

  • Describe what a digital therapeutic is and the FDA regulatory process
  • Understand the role digital therapeutics play in the treatment landscape for ADHD
  • Identify current digital therapeutics available for patients with ADHD and understand the data that supports their use

Who: Dr. Scott Kollins

Biography

Dr. Kollins is a licensed clinical psychologist in the state of North Carolina and spent more than 20 years on the faculty in the Department of Psychiatry and Behavioral Sciences at the Duke University School of Medicine, where he maintains an adjunct faculty appointment. While at Duke, he was also the co-lead for the Digital Health Solutions Initiative at the Duke Clinical Research Institute (DCRI). Prior to joining Akili, Dr. Kollins was the chief medical officer for Holmusk, the world’s leading real-world evidence company focused on behavioral health. Dr. Kollins has been ranked among the Top 100 Psychiatry faculty members in the U.S. with respect to NIH funding and also served as principal investigator on more than 50 industry-funded clinical trials, including Akili’s STARS-ADHD trial published in The Lancet Digital Health. His research has been published in nearly 200 scientific papers in peer-reviewed journals. Dr. Kollins received his undergraduate degree in psychology from Duke University in 1992 and earned his Master’s and Doctorate degrees in Clinical Psychology from Auburn University in 1995 and 1997, respectively. He completed his clinical internship at the University of Mississippi Medical Center, where he served as chief intern.

Visit Scott’s website here: https://www.akiliinteractive.com/